🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations Ashwin Kishtagari, MD and helping the next generations Vanderbilt University Medical Center Vanderbilt Health Dr. jordan berlin

Fantastic study & findings from Ashwin Kishtagari, MD & VUMC collaborators like Alex Bick ! Hopefully the start of many more studies to come.

🚨🚨Paper out! 🚨🚨 Delighted to share our work, now published in Nature Genetics 🧬! shorturl.at/94s5S We identified a targetable, chromothripsis-associated genetic event in blast phase (BP) MPN, a particularly poor prognostic subtype of acute leukaemia. 1/n 🧵👇

Remarkable work by Yash Pershad and team on CHIP dynamics over 16 years in ~7,000 women out now in Blood Journals Portfolio! Longitudinal CHIP studies remain rare - this depth of follow-up is invaluable. Correlates and Consequences of Clonal Hematopoiesis Expansion Rate: A 16-Year

How reliable is plasma cell-free DNA for detection of clonal hematopoiesis? Would love to chat about it tonight at the #EHA25 poster session! Poster PS-2315 :)

Long awaited results of #VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk #MDSsm. Subgroup analyses will be important. news.abbvie.com/2025-06-16-Abb…

Honored & humbled to receive #BeutlerPrize along w/#RadekSkoda. Measuring #MPN Symptoms & developing the 4 JAKi = #TEAM of dedicated MPN Patients/Investigators/#PharmaColleagues Claire Harrison #SergeVerstovsek J.J. Kiladjian #Vannuchi Robyn M. Scherber MD #JoyceNiblack Wake Forest University School of Medicine

Low blood cell counts drive cancer in explosive blood disorder: study news.vumc.org/2025/06/23/low…

Our new episode on overview of Menin Inhibitors in AML with Eytan Stein from Memorial Sloan Kettering Cancer Center just dropped! We had a great discussion on the landscape of menin inhibitors, along with some clinical pearls from Dr. Stein on management! share.transistor.fm/s/f91d6c00 Ashwin Kishtagari, MD

Excited to see our NHLBI work on infections and immunodeficiency in patients with #telomere biology disorders now published in Blood Journals Portfolio. >1/3 had significant infection history and nearly 1/2 t-lymphopenia. Fernando Catto & Fernanda Gutierrez-Rodrigues. ashpublications.org/blood/article-…

Great use of scDNAseq and other MRD techniques to show the power of precision oncology. Love it! Congratulations!! Taylor Lab UM Justin Watts MD Ferrell Lab Ashwin Kishtagari, MD

Happy to share our newest work out today in BCD evaluating disease classification and prognosis in the “world of myeloid malignancies”! Wonderful collaboration with Sanam Loghavi, MD صنم لغوی 🔬🧬 Elli Papaemmanuil, PhD Elsa Bernard and colleagues.

The recent EHA 2025 Congress showcased novel combinations for MDS and AML as well as a novel formulation of a drug for B-ALL: an opinion piece by Ashwin Kishtagari, MD of Vanderbilt University Medical Center. shorturl.at/RkY2M #EHA2025 #leusm #mdssm

Opinion: Top Studies From EHA 2025 CancerTherapyAdvisor cancertherapyadvisor.com/features/top-s…

A thoughtful and nuanced discussion on the results of MIDAS trial #mmsm #bmtsm Raj Chakraborty Eddie Cliff Meera Mohan podcasts.apple.com/us/podcast/blo…

We are excited to share our work on "closing the loop" 🔄 - a framework enabling single-cell foundation models (scFMs) to learn from experimental validation and dramatically improve their predictive accuracy! (1/n)

Delighted to collaborate on this study led by Jie Liu Kelly Bolton MD PhD describing how germline genetic variation influences the trajectory of clonal hematopoiesis to hematologic malignancy nature.com/articles/s4158… Nature Genetics

Very excited to share our paper investigating the evolution of therapy-related CH in myeloma pts treated w/ or w/o LEN. Can we predict the risk for second blood cancer in myeloma pts? Grateful for the collaboration with UChicagoCancerCenter myeloma program. nature.com/articles/s4137…

As FDA Oncology’s ODAC weighed in today on the future of belantamab-based triplets, revisit this timely episode of Blood Cancer Talks with Hang Quach, where we break down DREAMM-7 & DREAMM-8 and explore belantamab’s evolving role in myeloma treatment. 🎧 Eddie Cliff